Halozyme Therapeutics (HALO) EBITDA (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly EBITDA of $184.5 million for Q1 2026, up 30.37% year-over-year from $141.5 million in Q1 2025, and up 298.64% quarter-over-quarter from -$92.9 million in Q4 2025.
Halozyme Therapeutics (HALO) EBITDA (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported EBITDA for 17 consecutive years, with $184.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA rose 30.37% year-over-year to $184.5 million; the TTM figure through Mar 2026 stood at $512.0 million (down 14.31% YoY), while the FY2025 annual figure was $469.0 million, down 14.95% from the prior year.
- EBITDA improved to $184.5 million in Q1 2026 per HALO's latest filing, from -$92.9 million in the prior quarter.
- Across five years, EBITDA topped out at $217.9 million in Q3 2025 and bottomed at -$92.9 million in Q4 2025.
- Historically, EBITDA has averaged $106.5 million across 5 years, with a median of $95.5 million in 2024.
- Annual changes were most pronounced in 2023 — EBITDA surged 177.33% — and 2025, when it tumbled 152.93%.
- Halozyme Therapeutics' EBITDA stood at $74.5 million in 2022, then surged by 35.6% to $101.0 million in 2023, then surged by 73.7% to $175.5 million in 2024, then sank by 152.93% to -$92.9 million in 2025, then surged by 298.64% to $184.5 million in 2026.
- Business Quant data shows HALO's EBITDA at $184.5 million in Q1 2026, -$92.9 million in Q4 2025, and $217.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 287.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 287.65 Mn |
| Mar 31, 2026 | 184.52 Mn |
| Dec 31, 2025 | -92.89 Mn |
| Sep 30, 2025 | 217.92 Mn |
| Jun 30, 2025 | 202.44 Mn |
| Mar 31, 2025 | 141.54 Mn |
| Dec 31, 2024 | 175.50 Mn |
| Sep 30, 2024 | 163.20 Mn |
| Jun 30, 2024 | 117.24 Mn |
| Mar 31, 2024 | 95.54 Mn |
| Dec 31, 2023 | 101.04 Mn |
| Sep 30, 2023 | 88.28 Mn |
| Jun 30, 2023 | 94.46 Mn |
| Mar 31, 2023 | 53.80 Mn |
| Dec 31, 2022 | 74.51 Mn |
| Sep 30, 2022 | 83.29 Mn |
| Jun 30, 2022 | 34.06 Mn |
| Mar 31, 2022 | 75.67 Mn |
| Dec 31, 2021 | 56.53 Mn |
| Sep 30, 2021 | 75.59 Mn |